Novo Nordisk A/S (NYSE:NVO) is reporting third quarter earnings results on Friday 30th October 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.71 per share.
For the full year, analysts predict revenues of $ 20386.40 million, while looking forward to income of $ 2.87 per share.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 4,860.00 million ~ $ 4,860.00 million
Full Year 2020 topline are forecasted in a range of$ 19,218.00 million ~ $ 19,767.00 million
Click Here For More Historical Outlooks Of Novo Nordisk A/S
Previous Quarter Performance
Novo Nordisk A/S unwinded income for the second quarter of $ 0.67 per share, from the revenue of $ 4,429.00 million.
Stock Performance
Shares of Novo Nordisk A/S traded low $ -0.22 or -0.33 percent on Thursday, reaching $ 66.33 with volume of 1.30 million shares. Novo Nordisk A/S has traded high as $ 67.24 and has cracked $ 66.12 on the downward trend
According to the previous trading day, closing price of $ 66.33, representing a 35.15 % increase from the 52 week low of $ 49.24 and a 9.84 % decrease over the 52 week high of $ 73.81.
The company has a market capital of $ 155.86 billion and is part of the Healthcare sector and Biotechnology industry.
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
